ArticleDermatology and therapy2026
Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is an autoimmune disease affecting approximately 2.1% of the population. JAK inhibitors represent a therapeutic breakthrough for severe AA, yet objective tools for monitoring treatment response remain limited. The objective of this study was to correlate trichoscopic and reflectance confocal microscopy (RCM) features with clinical changes in patients with severe AA treated with JAK inhibitors (upadacitinib and baricitinib) over 60 weeks.
methodsTwenty patients with severe AA were enrolled. Patients were treated with upadacitinib 15 mg/day or baricitinib 4 mg/day. Clinical (Severity of Alopecia Tool score), trichoscopic, and RCM evaluations were performed at baseline and every 12 weeks thereafter.
resultsMean Severity of Alopecia Tool (SALT) decreased from 85% at baseline to 17% at week 60. Upadacitinib treated patients showed faster early response (32.6%% SALT reduction at week 12 vs. 5.2% increase with baricitinib), though both groups achieved comparable outcomes by week 60 (SALT 17%). Trichoscopy showed progressive reduction of activity markers: (yellow dots, black dots, broken hairs, and exclamation mark hairs) with characteristic regrowth sequence: short vellus hairs, upright regrowing hairs, terminal hairs. RCM identified three parameter categories: (1) inflammatory activity markers (epidermal infiltration, bright rimming, luminal bright material, cadaverised hairs), with persistent diffuse follicular inflammation and perifollicular muffle; (2) transient collagen remodelling features without fibrosis; and (3) recovery markers, including follicular normalisation (strongest RCM predictor of response) and vellus-to-terminal transition.
conclusionsJAK inhibitors demonstrated sustained efficacy in severe AA. Multimodal assessment combining SALT, trichoscopy, and RCM enables precise biological response monitoring. RCM uniquely detects subclinical perifollicular inflammation persisting despite clinical improvement, potentially predicting relapse risk after treatment discontinuation.
Indexed as
Identifiers
42825997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.